Market news

Detailed price information for Flowserve Corp (FLS-N) from The Globe and Mail including charting and trades.

Detailed price information for I C U Medical Inc (ICUI-Q) from The Globe and Mail including charting and trades.

The sale was part of a trading plan established in June.

The sale was part of a trading plan established in June.

Bonnell retains 62,443 direct shares.

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,

Brian Michael Bonnell, Chief Financial Officer, on August 31, 2026, sold 9,307 shares in ICU Medical

SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on September 9-10, 2026 Company management will attend the Wells Fargo 21st Annual Healthcare Conference, held at the Encore Boston Harbor in Boston, MA, participating in one-on-one meetings on Wednesday, Sept

The Otsuka ICU Medical joint venture, formed last year by ICU Medical and Otsuka Pharmaceutical Factory, is nearly doubling its Austin manufacturing campus in its first major expansion.

Let’s dig into the relative performance of ICU Medical (NASDAQ:ICUI) and its peers as we unravel the now-completed Q2 medical devices & supplies - cardiology, neurology, vascular earnings season.

ICU Medical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 9.3%. The stock now trades at $182.79, marking a 23.3% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Detailed price information for Novanta Inc (NOVT-Q) from The Globe and Mail including charting and trades.

Detailed price information for I C U Medical Inc (ICUI-Q) from The Globe and Mail including charting and trades.

ICU Medical’s second quarter results were well received by the market, with management highlighting robust performance in the Infusion Systems and Consumables segments as key drivers. CEO Vivek Jain emphasized that North America led growth, and noted that “record quarters” in both pumps and consumables reflected broad-based demand and incremental wins. Operational efficiencies stemming from IT system integration and facility consolidation also contributed to improved operating margins. Managemen

Detailed price information for I C U Medical Inc (ICUI-Q) from The Globe and Mail including charting and trades.

Detailed price information for Clear Secure Inc Cl A (YOU-N) from The Globe and Mail including charting and trades.

Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.

ICU Medical Inc (NASDAQ:ICUI) reported strong Q2 earnings of $2.37 per share and raised its FY2026 guidance. Analysts have increased price targets for the stock.

While the top- and bottom-line numbers for ICU Medical (ICUI) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ICU Medical (ICUI) delivered earnings and revenue surprises of +24.08% and +2.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for I C U Medical Inc (ICUI-Q) from The Globe and Mail including charting and trades.

ICU Medical (ICUI) reported Q2 adjusted earnings late Thursday of $2.37 per diluted share, up from $

SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2026. Second Quarter 2026 Results The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. Second quarter 2026 GAAP revenue increased 1% year-over-year; however, excluding the impact of the IV Sol

Detailed price information for I C U Medical Inc (ICUI-Q) from The Globe and Mail including charting and trades.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Detailed price information for Brinker International (EAT-N) from The Globe and Mail including charting and trades.